4-(2-Oxoazepan-1-yl)piperidine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(2-Oxoazepan-1-yl)piperidine-1-carboxylic acid
• 英文别名: 4-(2-oxoazepan-1-yl)piperidine-1-carboxylic acid
• 化学式: C₁₂H₂₀N₂O₃
• 分子量: 240.3
• InChiKey: SHHFGAXIYUQLEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  60.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Pharmaceutical compounds
  申请人：Heptares Therapeutics Limited

  公开号：US10787447B2

  公开（公告）日：2020-09-29

  This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where Y, R1, R2 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 和/或 M4 受体的激动剂，可用于治疗由毒蕈碱 M1 和 M4 受体介导的疾病。本发明还提供了含有该化合物的药物组合物以及该化合物的治疗用途。所提供的化合物为式 其中 Y、R1、R2 和 R4 如本文所定义。
• BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR
  申请人：Heptares Therapeutics Limited

  公开号：EP3810614A1

  公开（公告）日：2021-04-28
• PHARMACEUTICAL COMPOUNDS
  申请人：Heptares Therapeutics Limited

  公开号：US20210002271A1

  公开（公告）日：2021-01-07

  This invention relates to compounds that are agonists of the muscarinic M 1 and/or M 4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M 1 and M 4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where Y, R 1 , R 2 and R 4 are as defined herein.
• [EN] BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR<br/>[FR] COMPOSÉS PONTÉS À UTILISER EN TANT QU'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M1 ET/OU M4
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2019243851A1

  公开（公告）日：2019-12-26

  This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where Y, R1, R2 and R4 are as defined herein.